Humana

Humana AB Q4 2025 Earnings Preview: Revenue Expected to be $2.56 Billion and Earnings to be $0.91 per Share

哈门那

Humana's 15min chart triggered MACD Death Cross, KDJ Death Cross.

Humana Launches Scholars Program to Support Nursing Students and Address Workforce Shortage in Home Health Care.

Medicare Advantage Members Benefit from Value-Based Care: Improved Outcomes and Preventive Care

Zynex Enters Provider Agreement with Humana for Non-Invasive Pain Management Devices

Catalyst<ul> <li>Recent Bullish Engulfing and Marubozu White candlestick patterns indicate strong short-term buying pressure for HUM.</li></ul>Risk<ul> <li>Fund flow analysis shows negative net inflow across all order sizes, suggesting investor caution and potential selling pressure.</li> <li>Analyst ratings show a consensus Sell recommendation, indicating pessimism about HUM's outlook.</li></ul>

Key Factors

Humana (HUM) closed 0.20% higher on February 6, 2026, with a trading volume of $0.39 billion despite a broader sector sell-off due to weak Medicare Advantage rate increases for 2027.Humana reaffirmed its full-year adjusted EPS guidance of $17 for 2025, with Q3 earnings exceeding expectations but facing near-term concerns from elevated medical and pharmacy costs.Humana launched the Humana Scholars program with a $125,000 investment to support nursing students and address workforce shortages in home health care, partnering with Jefferson Community and Technical College.Zynex entered provider agreements with Humana, enabling Humana members to access Zynex's non-invasive pain management devices, including the NexWave, expanding Zynex’s reach to nearly 20 million people.Humana shares dropped over 20% on January 27, 2026, following a proposed 0.09% Medicare Advantage payment increase for 2027, a sharp decline from the 5.06% increase in 2026.

HUM News